Astria Therapeutics, Inc. (ATXS)
12.94
-0.18
(-1.41%)
USD |
NASDAQ |
Dec 05, 16:00
12.94
0.00 (0.00%)
After-Hours: 17:44
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 738.39M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 29.39% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1055.55 |
| Price to Book Value | 5.353 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0191 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.65% |
Profile
| Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA. |
| URL | http://www.astriatx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 18, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA. |
| URL | http://www.astriatx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 18, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |